


We claim:

1. A compound of formula (I)



p is 0, 1, or 2;

q is 0, 1, 2, or 3;

y is 0, 1, or 2; and z is 0, 1, or 2;

X₁ and X₂ are each independently is CH, or N;

B is O, NR^t, S, SO, SO₂, or CH₂;

D is OH, CONR⁶R⁷, SO₂NR⁶R⁷, NR⁶COR⁷, or NR⁶R⁷; provided that when B is O, D is not CONR⁶R⁷;

R¹ and R² are independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, C₁-C₁₀ alkylaryl, C₄-C₁₀ alkylcycloalkane, and (CH₂)_nC(O)R⁸; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, C₃-C₈ cycloalkyl, C₁-C₈ alkylaryl, and C(O)C₁-C₈ alkyl; and wherein R¹ and R² may optionally combine with each other to form a 4, 5, 6, or 7-membered nitrogen-containing heterocycle which nitrogen-containing heterocycle may further have substituents selected from the group consisting of oxo, amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, C₁-C₃ alkylaryl, C(O)C₁-C₈ alkyl, CO(O)C₁-C₈ alkyl, halo, C₁-C₃ haloalkyl;

R³ and R^{3'} are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, aryl, C₁-C₈ alkylcycloalkyl, and C₁-C₈ alkylaryl;

R⁴ and R⁵ are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₁-C₈ alkoxy, halo, C₁-C₈ haloalkyl, phenyl, aryl, C₁-C₈ alkylaryl, (CH₂)_mNSO₂C₁-C₈ alkyl, (CH₂)_mNSO₂phenyl, (CH₂)_mNSO₂aryl, -C(O)C₁-C₈ alkyl, and -

C(O)OC₁-C₈ alkyl; wherein each R⁴ and R⁵ is attached to its respective ring only at carbon atoms; wherein m is 1 or 2; and n is 1, 2, or 3;

R⁶ and R⁷ are each independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C(O)C₁-C₈ alkyl, aryl, C₁-C₈ alkylaryl, C₃-C₇ cycloalkane, C₁-C₆ alkylcycloalkane, (CH₂)_mC(O)OR⁸, and (CH₂)_mNSO₂R⁸; wherein each of the alkyl, alkenyl, and aryl groups are optionally substituted with one to two groups independently selected from C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, and C₁-C₈ alkylaryl; and wherein when D is NR⁶R⁷ or SO₂NR⁶R⁷, the R⁶ and R⁷ groups may independently combine with each other, and with the nitrogen atom to which they are attached to form a 4, 5, 6, or 7-membered nitrogen containing heterocycle which nitrogen containing heterocycle may optionally have substituents selected from the group consisting of oxo, amino, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, and C₁-C₈ alkylaryl;

R^t is selected from the group consisting of hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, phenyl, and C₁-C₈ alkylaryl;

R⁸ is independently selected from hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, phenyl, benzyl, and C₅-C₈ alkylaryl;

or a pharmaceutically acceptable salt, solvate, prodrug, enantiomer, racemate, diastereomer, or mixture of diastereomers thereof.

2. The compound according to claim 1 wherein the X₁ is CH, and X₂ is CH or N

3. A compound according to Claim 1 wherein X₁ is N and X₂ is CH or N.


4. A compound according to Claim 1 wherein X₁ and X₂ are both CH.

5. A compound according to Claim 1 wherein X₁ and X₂ are both N. A compound according to Claim 1 wherein D is CH₂ or NH or S.

6. A compound according to Claim 1 wherein y is 0 or 1, and R⁴ is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, benzyl and ethoxy.

7. A compound according to Claim 1 wherein z is 0 or 1, and R^5 is independently selected from the group consisting of fluoro, chloro, bromo, methoxy, ethoxy, methyl, ethyl, isopropyl, trifluoromethyl, phenyl, and benzyl.

8. A compound according to Claim 1 wherein R^1 and R^2 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 2-methylpentyl, t-butyl, cyclopropyl, phenyl,



9. The compound according to Claim 1 wherein R^6 and R^7 are each independently selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, and phenyl.

10. A compound selected from the group consisting of:

- 4-[4-(2-Methylamino-ethyl)-phenoxy]-phenol,
- 4-{4-[2-(Benzyl-methyl-amino)-ethyl]-phenoxy}-phenol,
- Acetic acid 4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl ester,
- 6-[4-(Benzylamino-methyl)-phenylsulfanyl]-nicotinamide,
- 6-{4-[(3-Methyl-butylamino)-methyl]-phenylsulfanyl}-nicotinamide,
- 6-{4-[(2-Pyridin-4-yl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide,
- 6-[4-(Phenethylamino-methyl)-phenylsulfanyl]-nicotinamide,
- 6-{4-[(Cyclopropylmethyl-amino)-methyl]-phenylsulfanyl}-nicotinamide,

6-{4-[(2-Thiophen-2-yl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide,
 6-{4-[(3-Phenyl-propylamino)-methyl]-phenylsulfanyl}-nicotinamide,
 6-{4-[(3-Methyl-butylamino)-methyl]-phenylsulfanyl}-nicotinamide,
 4-[4-(Phenethylamino-methyl)-benzenesulfonyl]-benzamide,
 4-[4-(Phenethylamino-methyl)-benzenesulfinyl]-benzamide,
 6-[4-(2-Benzylamino-ethyl)-phenylamino]-nicotinamide,
 6-{4-[2-(Cyclohexylmethyl-amino)-ethyl]-phenylamino}-nicotinamide,
 6-{4-[(2-Pyridin-4-yl-ethylamino)-methyl]-phenylsulfanyl}-nicotinamide,
 6-[4-(Benzylamino-methyl)-phenylamino]-nicotinamide,
 6-{4-[(Cyclohexylmethyl-amino)-methyl]-phenylamino}-nicotinamide,
 6-[4-(Phenethylamino-methyl)-phenylamino]-nicotinamide,
 6-{4-[(3-Methyl-butylamino)-methyl]-phenylamino}-nicotinamide,
 N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-acetamide,
 N-{4-[4-(2-Hexylamino-ethyl)-phenoxy]-phenyl}-acetamide,
 N-[4-(4-{2-[(Thiophen-2-ylmethyl)-amino]-ethyl}-phenoxy)-phenyl]-acetamide,
 N-(4-{4-[2-(3-Phenyl-propylamino)-ethyl]-phenoxy}-phenyl)-acetamide,
 N-(4-{4-[2-(2-Cyclohexyl-ethylamino)-ethyl]-phenoxy}-phenyl)-acetamide,
 N-{4-[4-(2-Phenethylamino-ethyl)-phenoxy]-phenyl}-acetamide,
 N-{4-[4-(2-Propylamino-ethyl)-phenoxy]-phenyl}-acetamide,
 N-{4-[4-(2-Pentylamino-ethyl)-phenoxy]-phenyl}-acetamide,
 N-(4-{4-[2-(Cyclohexylmethyl-amino)-ethyl]-phenoxy}-phenyl)-acetamide,
 N-(4-{4-[2-(2-Trifluoromethyl-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide,
 N-[4-(4-{2-[(Furan-2-ylmethyl)-amino]-ethyl}-phenoxy)-phenyl]-acetamide,
 N-(4-{4-[2-(3-Chloro-benzylamino)-ethyl]-phenoxy}-phenyl)-acetamide,
 4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenylamine,
 N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-benzamide,
 Morpholine-4-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
 N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-2-methoxy-acetamide,
 Furan-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
 Isoxazole-5-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
 Thiophene-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
 N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-isonicotinamide,

3,5-Dimethyl-isoxazole-4-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
2-tert-Butyl-5-methyl-2H-pyrazole-3-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
5-Methyl-isoxazole-3-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
4-Methyl-[1,2,3]thiadiazole-5-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-3-methylsulfanyl-propionamide,
Quinoxaline-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
N-{4-[4-(2-Benzylamino-ethyl)-phenoxy]-phenyl}-nicotinamide,
Pyridine-2-carboxylic acid {4-[4-(2-benzylamino-ethyl)-phenoxy]-phenyl}-amide,
N-(6-{4-[(3-Methyl-butylamino)-methyl]-phenoxy}-pyridin-3-yl)-acetamide,
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer and diastereomeric mixture thereof.

11. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of Claims 1 to 10 in association with a carrier, diluent and/or excipient.

12. A method for blocking a mu, kappa, delta or receptor combination (heterodimer) thereof in mammals comprising administering to a mammal requiring blocking of a mu, kappa, delta or receptor combination (heterodimer) thereof, a receptor blocking dose of a compound according to any one of Claims 1 to 10, or a pharmaceutically acceptable salt, enantiomer, racemate, mixture of diastereomers, or solvate thereof.

13. A method of treating or preventing obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I.

14. A method according to Claim 13 wherein the Related Diseases is selected from the group consisting of diabetes, diabetic complications, diabetic retinopathy,

atherosclerosis, hyperlipidemia, hypertriglycemia, hyperglycemia, and hyperlipoproteinemia.

15. A method of treating and/or preventing diseases related to obesity including irritable bowel syndrome, nausea, vomiting, depression, smoking and alcohol addiction, sexual dysfunction, substance abuse, drug overdose, addictive behavior disorders, compulsive behaviors, and stroke comprising administering a therapeutically effective amount of a compound of formula I.

16. A method of suppressing appetite in a patient in need thereof, comprising administering a therapeutically effective amount of a compound of formula I.

17. Use of a compound of formula I in the manufacture of a medicament for the treatment and/or amelioration of the symptoms associated with obesity and Related Diseases comprising administering a therapeutically effective amount of a compound of formula I to a patient in need thereof.